Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 5/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27974517 | 0.84 | CYP1A2 (0.46) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL28173245 | 0.83 | CYP3A4 (0.40) | CYP1A2SLC7A5SLC1A3GRIA1GRIA2 | |
| SCHEMBL4727798 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL60911 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL14798187 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL4726518 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL1678922 | 0.81 | CYP1A2 (0.44) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| Hydrochloric Acid SCHEMBL6697015 | 0.81 | TYR (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL7001068 | 0.81 | SLC7A5 (0.44) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL52215 | 0.81 | CYP2C9 (0.47) | CYP1A2SLC7A5PKMALPIPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111413379-A | Preparation method and application of chiral Ni-MOF/NiSR core-shell composite material | 济南大学 | 2020-07-14 | — | — | CN | claimed |
| US-20240010735-A1 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR AMYOTROPHIC LATERAL SCLEROSIS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2023134771-A1 | PHARMACEUTICAL COMPOSITION OF ANTI-CTLA-4 ANTIBODY AND USE THEREOF | 上海君实生物医药科技股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | disclosed |
| CN-111413379-A | Preparation method and application of chiral Ni-MOF/NiSR core-shell composite material | 济南大学 | 2020-07-14 | — | — | CN | disclosed |
| CN-109562163-A | Monoclonal antibodies specific to EGFL6 and methods of use thereof | 得克萨斯大学体系董事会 | 2019-04-02 | — | — | CN | disclosed |
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-8946148-B2 | Modified insulin polypeptides and their uses | AMBRX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120094297-A1 | Method For Producing Protein | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| US-20120034209-A1 | Treatment | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2011051349-A1 | ANTIBODIES TO ION CHANNELS | UCB PHARMA S.A. (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051350-A1 | FUNCTION MODIFYING NAV 1.7 ANTIBODIES | UCB PHARMA S.A. (BE) | 2011-05-05 | — | — | WO | disclosed |
| EP-2314626-A1 | Antibody molecules having specificity for human IL-6 | UCB Pharma, S.A. (BE) | 2011-04-27 | — | — | EP | disclosed |
| US-20110081350-A1 | Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2011-04-07 | — | — | US | disclosed |
| US-20110082080-A1 | COMPOSITIONS AND METHODS OF USING THE HUMAN PROISLET PEPTIDE RECEPTOR | CUREDM GROUP HOLDINGS, LLC (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110059088-A1 | Protein involved in ovarian cancer | Cell Tech R&D Limited | 2011-03-10 | — | — | US | disclosed |
| US-7902154-B2 | Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same | FORHUMANTECH. CO., LTD. (KR) | 2011-03-08 | — | — | US | disclosed |
| EP-2287193-A1 | Antibody molecules having specificity for human IL-1 beta | UCB Pharma, S.A. (BE) | 2011-02-23 | — | — | EP | disclosed |
| US-7868134-B2 | Immunogenic peptides derived from sclerostin | UCB MANUFACTURING, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100298212-A1 | Modified Insulin Polypeptides and Their Uses | AMBRX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298212-A1 | Modified Insulin Polypeptides and Their Uses | IAPP, INSR, IGFBP4 | CYP1A2 4819/4885SLC7A5 2951/4885PKM 1078/4885 |
| US-20170107255-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | CYP1A2 4736/4885SLC7A5 3758/4885PKM 4047/4885 |
| US-10941182-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | CYP1A2 4736/4885SLC7A5 3758/4885PKM 4047/4885 |
| US-20110082080-A1 | COMPOSITIONS AND METHODS OF USING THE HUMAN PROISLET PEPTIDE RECEPTOR | PROKR1, GIPR, IAPP | CYP1A2 4885/4885SLC7A5 3593/4885PKM 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.